Pediatrix Medical Group, Inc.
MDHealthcareNASDAQMedical Care Facilities · Last scanned Oct 26, 2026
Scan Results
Daily timeframePediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. Valued at $2.38B, MD is a mid-cap name in its sector. The company offers clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through its network of affiliated neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; and inpatient and office-based clinical care to expectant mothers and unborn babies through its affiliated maternal-fetal medicine subspecialists, obstetricians and other clinicians, maternal-fetal medicine nurse practitioners, certified nurse midwives, sonographers, and genetic counselors.
Market Cap
$2.38B
Beta
0.61
P/E (TTM)
14.01
P/E (Fwd)
12.00
EPS (TTM)
$2.09
EPS (Fwd)
$2.44
ROE
20.4%
ROA
7.1%
Cash
$404.2M
Total Debt
$620.0M
Free CF
$160.8M
52W Change
68.0%
Annual Financials
Cash vs Debt
Where MD stands vs its 150-day and 200-day moving averages
As of the October 13, 2026 close, MD finished 11.24% above its 150-day moving average ($24.20) and 14.94% above its 200-day moving average ($23.42). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MD overbought or oversold?
At the October 13, 2026 close, MD's RSI(14) was 57.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, MD has $404.2M in cash with $620.0M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $160.8M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 20.4%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 7.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $1.97B (2022) to $1.91B (2025).
With a beta below 0.7, Pediatrix Medical Group, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MD.